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ABSTRACT
Aim of the study. We investigated whether D-dimer (DD) concentration is elevated in cerebral venous and sinus thrombosis 
(CVST), as has been reported in the literature.
Clinical rationale for the study. CVST is a disease with variable clinical presentations and a challenging diagnosis. We looked into 
whether D-dimer concentration might be an indicator of CVST, and the need for neuroimaging tests correlated with clinical factors.
Materials and methods. We included all consecutive patients (mean age 41.6 years) with CVST treated in our neurology depart-
ment from 2014 to 2018 whose DD levels had been measured. DD concentrations were categorised as normal (≤ 0.5 μg/ml) or 
elevated (> 0.5 μg/ml). Appropriate imaging confirmed the diagnosis of CVST. The results were compared to those of a control 
group consisting of 22 age- and sex-matched patients (mean age 40 years) with a diagnosis of primary headache (tension type 
or migraine) hospitalised to exclude secondary causes.
Results. In 20 patients in the CVST study group, median level of DD was 1.0 + 0.57 μg/ml (range 0.19–2.45 μg/ml), compared to 
the control group’s mean DD level of 0.50 + 0.45 μg/ml (range 0.15–1.73 μg/ml), with p < 0.005. Higher DD levels were associated 
with complications of the disease and fatal course (p < 0.005). One female and one male patient died because of CVST with DD 
levels of (respectively) 2.45 and 1.80 μg/ml — the two highest concentrations in our study group.
Conclusions and clinical implications. DD concentration, especially in headache patients, may be a factor to predict CVST and an 
indicator for further diagnostic procedures with venography. But in clinical practice, low levels of DD cannot be taken to exclude CVST.
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Introduction
Cerebral venous and sinus thrombosis (CVST) is a rare 
cause of stroke which affects typically young adults, mainly 
females [1]. The incidence of CVST is probably about 3–4 cases 
per million in the general population [1], but there is no reliab-
le epidemiological data on this topic. It can have many overlap-
ping symptoms in the acute, subacute or chronic phases, with 
a lot of varying clinical manifestations. So, a confirmed CVST 
diagnosis presents many challenges in everyday clinical pra-
ctice. Known risk factors for CVST include pregnancy, recent 
childbirth, the use of oral contraceptives, prothrombotic states, 
coagulation disturbances, infections, dehydration, emaciation, 
and cancer, and if present these can make the diagnosis easier. 
In some cases however, no risk factors are recognised, and 
this can prolong the diagnostic process. It is unclear whether 
D-dimer (DD) levels reflect clinical presentation, radiological 
features of CVST involvement, and outcome in this disease. 
There are some studies showing that DD concentrations are 
elevated in CVST [9]. DD measurement is useful in patients 
suspected of CVST, and patients with elevated levels should 
be urgently sent for venography of CT or MR (depending 
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on their resolution and sensitivity in a hospital). But on the 
other hand, in clinical practice, low levels of DD cannot rule 
out the disease in patients with subacute or chronic disease 
[10], although Hiltunen at al. [10] concluded that high DD 
levels correlate with greater thrombus extension and acute 
onset of symptoms.  
In the study by Misra et al. [11], 26 patients with CVST had 
flight MR venography. In this study, DD was estimated and the 
results were positive in 20 patients and correlated with the du-
ration of symptoms but not with the extent of sinus thrombosis 
and the outcome of the disease [11]. The authors concluded 
that DD is a useful parameter in patients suspected of CVST, 
and they stated that all patients with positive DD test results 
should be urgently sent for MR imaging. In another prospec-
tive study [12], 233 CVST-suspected patients were enrolled. 
34 cases of CVST were confirmed using imaging modalities, 
whereas the other 199 cases served as mimic controls. DD and 
fibrinogen levels of all patients and controls were measured 
before imaging and treatment. In the CVST patients, more than 
94% had DD elevation. Additionally, the authors claimed that 
DD may serve as an important screening tool to determine the 
urgency of obtaining magnetic resonance imaging/magnetic 
resonance venography or digital subtraction angiography in 
patients presenting with clinical symptoms that are suspected 
of CVST, because DD might predict CVST. It is very important 
to make the proper diagnosis without delay because recent 
improvements in treatment, implemented early in the disease 
course, have resulted in better outcomes [13–16]. 
We were interested in confirming whether DD concen-
trations in our population were indeed elevated in CVST as 
reported in those studies, and whether DD might be a factor 
predicting the need for neuroimaging tests such as venography 
of CT (veno-CT) or MR correlated with clinical factors.
Clinical rationale for the study
It is known that DD levels correlate with deep vein throm-
bosis (DVT) [2, 3] and pulmonary thromboembolism [4–6], 
and that they might be a marker of CVST. DD levels are closely, 
strongly and positively related to the clinical status of DVT 
[2, 7] and some findings have suggested that a high plasma 
DD level during the course of acute stroke (initially normal) 
can help detect DVT on duplex venous ultrasonography [8]. 
Proving that DD concentrations also correlate with the risk of 
CVST would have important clinical usefulness.
Materials and methods 
Study design
We included in the study all consecutive patients with 
CVST diagnosis treated in our hospital from 2014 to June 
2018. The study group consisted of 20 patients: 15 female 
(75%) and five male (25%), mean age 42 years (range 20–84). 
Before the disease all patients had 0 in modified Rankin 
Scale. Demographic characteristics with involved sinuses and 
DD levels are presented in Table 1.  Our age- (p = 0.7) and 
sex- (p = 0.8) matched control group consisted of 22 patients 
with primary headache (tension type or migraine), mean age 
40 years (range 19–79) hospitalised because of headache with 
the exclusion of any serious neurological disease. The control 
group consisted of 16 females (73%) and six males (27%). 
Controls were recruited from our clinic, after performing 
angiography (CT or MR) and measuring DD level (mean 0.50 
+ 0.45 μg/ml; min. = 0.15; max.= 1.73 μg/ml). All patients with 
a DD level higher than 0.5 μg/ml had a cause for it: four had 
a urinary tract infection, one had prostate cancer, and one was 
pregnant. All the individuals in our study groups (control and 
CVST) were Caucasian. Mean age for study groups was not 
significantly different (t-Student test — t = 0.32; p = 0.75). Sex 
of patients for study groups was also not significantly different 
(Pearson χ2 = 0.028; p = 0.87).
Patients with CVST diagnosis
DD levels measured before initiation of anticoagulant 
treatment (if needed) were, in mean level in the study group, 
1.0 + 0.57 μg/ml. Lilliefors test (p > 0.2) and Shapiro-Wilk 
test (W = 0.96; p = 0.52) showed that DD was normally 
distributed in the study group. DD was categorised as low 
(≤ 0.5 μg/ml), or increased (> 0.5 μg/ml; and in this range high, 
when > 2.0 μg/ml). Based on delay from symptoms onset to 
hospital presentation, the mode of onset was categorised as 
acute (< 3 days), subacute (4–7 days), or chronic (> 7 days). 
9/20 (45%) of our patients were categorised as acute ones, 
eight (40%) as subacute, one (5%) as chronic, and two (10%) 
as unknown (because of unconsciousness and insufficient 
medical information). 
20 cases of CVST were diagnosed within this period in our 
hospital with veno-CT (Fig.1 A, B, C) (performed within two 
hours of notification to the hospital emergency department 
and  from two hours of symptoms onset to 60 days in the case 
of one patient) and were consecutively enrolled in this study. 
The number and the type of sinuses involved are presented in 
Table 1. CVST patients who had a plasma DD test (20 cases) 
were included and divided into two groups: the elevated DD 
group (> 0.5 μg/ml) comprised 15 (75%) patients, and the nor-
mal DD group (≤ 0.5 μg/ml) consisted of five (25%) patients. 
Only one female patient had high levels of D-dimer (more 
than 2.00 μg/ml) – 2.45 μg/ml with a fatal course comprising 
stroke (Fig. 2 A, B, C, D) and death. The next highest DD level 
was 1.8 μg/ml in the case of a male patient, also with a fatal 
course of the disease. Clinical data such as: time of symptoms 
onset, type of symptoms during admission to emergency de-
partment, other symptoms and complications that appeared 
during hospitalisation, course of CVST, and prior risk factors 
are set out in Table 2. 
It is important to emphasise that 17/20 (85%) of 
our CVST patients complained of headache, 2/20 (10%) 
were asymptomatic, and 1/20 (5%) lost consciousness. 
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Complications of CVST included 3/20 (15%) ischaemic 
stroke, 3/20 (15%) subarachnoid haemorrhage (SAH), 
1/20 (5%) haemorrhagic stroke, and 2/20 (10%) seizures. In 
6/20 (30%), focal neurological symptoms were recognised. 
The patients were compared in terms of demographic data, 
clinical manifestations, and laboratory and imaging data, 
using inferential statistical methods. Demographic char-
acteristics of the control group with type of neuroimaging 
performed, DD levels and risk factors are set out in Table 
3. All patients with CVST were treated with low molecular 
weight heparin given subcutaneously. In cases with favour-
able outcomes, after about two weeks the treatment was 
changed for oral vitamin K antagonists.
Statistical analysis
Statistical analysis was carried out using Statistica 13.3. 
P-values of < 0.05 were considered statistically significant. 
Normality of distribution in the study and control groups 
was performed using the Lilliefors Test and the Shapiro-Wilk 
Test. DD levels were compared across the study and control 
groups performing t-tests and non-parametrical tests: the 
Mann-Whitney U Test and Kolmogorov-Smirnov Test. Vari-
ances were checked using Levene’s Test.
Results
The t-test showed that the CVST group (20 cases) had 
significantly higher levels of DD (t = 3.49; p = 0.0001) 
compared to the control group (22 cases) (Fig.3), and the 
variances were not significantly different (F-test: F = 1.62; 
p = 0.28; Levene’s Test: F (1.40) = 1.25; p = 0.27). Since 
DD was not normally distributed in the control group, 
non-parametric tests were performed too. Mann-Whitney 
U Test (p = 0.001) and Kolmogorov-Smirnov Test (p < 0.005) 
showed that distributions of DD in the study and control 
groups were different.
Patients with elevated DD levels were more likely to have 
a more severe course of the disease with serious complications 
such as stroke, subarachnoid haemorrhage and seizures (t-test: 
t = 3.43; p = 0.003 and t = 2.98; p = 0.008, respectively); the 
variances were not significantly different (F-test: F = 1.25; 
p = 0.68; Levene’s test: F (1.18) = 0.003; p = 0.95). 
There was no significant difference in DD level between 
the groups with an earlier time of onset, shorter symptoms 
duration, more risk factors, and higher number of affected 
venous sinuses (p > 0.05), probably due to the small number 
of patients in the study group.
Figure 1. Direct visualisation of thrombosis on vascular imaging. A. Angio-MR with thrombus in left sigmoid sinus. B. Angio-CT with throm-
bosis of right transverse sinus. C. Angio-CT with thrombus in superior sagittal sinus
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Table 1. Data of study group
Age Sex DD, μg/ml Involved sinuses Number of involved sinuses Course of the CVST
1. 29 F 1.55 Sigmoid;
Right transverse;
Inferior sagittal;
Straight  
4 Full recovery
2. 21 M 1.60 Superior sagittal;
Right transverse and sigmoid
3 Full recovery
3. 67 M 1.80 Superior sagittal;
Right transverse
2 Fatal: death
4. 48 F 0.32 Left transverse 1 Full recovery
5. 34 M 0.28 Right transverse 1 Full recovery
6. 42 F 1.02 Superior sagittal;
Right transverse
2 Full recovery
7. 38 F 0.19 Right transverse and sigmoid 2 Full recovery
8. 84 M 1.19 Left transverse 1 Full recovery
9. 26 F 0.87 Superior sagittal;
Right transverse and sigmoid
3 Full recovery
10. 29 M 1.35 Superior sagittal;
Right transverse and sigmoid
3 Full recovery
11. 20 F 0.37 Right transverse 1 Full recovery
12. 29 F 2.45 Superior sagittal;
Venous stroke
1 Fatal: stroke and death
13. 65 F 0.45 Right sigmoid 1 Full recovery
14. 27 F 1.40 Superior sagittal;
Right transverse and sigmoid
3 Full recovery
15. 32 F 0.95 Left transverse and sigmoid 2 Full recovery
16. 30 F 1.55 Superior sagittal;
Left transverse and sigmoid; Straight sinus;
Great cerebral vein;
Cavernous sinuses
5 Full recovery
17. 62 F 1.00 Left transverse and sigmoid 2 Full recovery
18. 43 F 1.10 Superior sagittal;
Right transverse and sigmoid
3 Full recovery
19. 67 F 1.01 Right sigmoid 1 Full recovery
20. 40 F 0.79 Straight 1 Full recovery
CVT — cerebral venous and sinus thrombosis; DD — D-dimer; F — female; M — male
Discussion and clinical implications
Our study found that DD is elevated in patients with 
a CVST diagnosis, as other authors have reported [9]. Additio-
nally, we looked into whether an elevated DD concentration is 
related to a worse course of the disease and its complications. 
We did not confirm a statistical correlation between a higher 
DD level and an earlier time of onset, shorter symptoms dura-
tion, more risk factors, and number of affected venous sinuses. 
We acknowledge that our study is limited because of the 
small number of patients in the study group, but this work is 
a preliminary one and our patients were consecutively ho-
spitalised in our department from 2014 to June 2018. Thus, 
probably the correlations are negative due to the small number 
of patients in the study group. It is worth noting that 25% of 
our CVST patients had a normal level of D-dimer. In clinical 
practice, low levels of DD cannot rule out CVST in patients 
with (especially) subacute or chronic disease. High DD levels 
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Figure 2. MRI of acute intracerebral haemorrhage of left brain hemisphere due to CVST. A. Susceptibility weight imaging. B. Diffusion weight 
imaging. C. Fluid-attenuated inversion recovery imaging. D. Apparent diffusion coefficient technique
Table 2. Clinical features of patients with CVST
Time from  
symptoms  
onset, days
Symptoms on onset Other symptoms and signs Complications Prior risk factors
6 Headache - - Oral contraception
4 Headache, nausea - - -
Not known Coma Coma Stroke, pneumonia Infection, cachexia
1 Headache, nausea, vertigo Nystagmus, vomiting - Oral contraception
3 Headache, nausea Vomiting - Otitis media, sinusitis
6 Headache, nausea Vomiting - Oral contraception, mastoiditis 
10 Headache Left face hypoesthesia - -
3 Headache, vertigo, nausea Vomiting, positive Romberg test, 
cerebellar gait
Seizure,
SAH
-
3 Headache, nausea, vertigo Vomiting - Oral contraception, sinusitis
3 Headache Vomiting - -
7 Headache - - Otitis media, sinusitis
1 - Aphasia, right hemiparesis Seizure, haemorrhagic  
stroke
Postpartum period
Not known Asymptomatic - - Smoking
4 Headache - Ischaemic stroke, SAH Oral contraception, smoking, 
obesity
7 Headache - SAH Oral contraception
1 Headache Aphasia, right hemiparesis Ischaemic stroke Oral contraception, obesity
3 Headache Left hemianesthesia - Ischaemic stroke
3 Headache - - -
60 Headache - - Otitis media
7 Headache - - Raynaud disease, Hyperhomocys-
teinemia
SAH — subarachnoid haemorrhage
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Table 3. Clinical data of control group (patients with diagnosis of primary headache)
Sex Age Type of headache D-dimer. ug/ml CRP. mg/l Normal vascular 
brain imaging
Time from 
symptoms on-
set (days)
Important concomi-
tant disorders
F 25 Tension type 1.66 38.9 Angio-CT 28 Urinary tract infection
F 45 Migraine 0.64 1.0 Angio-CT 7 Urinary tract infection
F 25 Tension type 0.32 1.0 Angio-MR 1
M 79 Tension type 0.86 3.2 Angio-MR > 365 Urinary tract infection
M 35 Tension type 0.25 1.0 Angio-MR 9
F 36 Tension type 0.19 1.0 Angio-CT 60
F 19 Tension type 0.15 0.3 Angio-MR 7
M 41 Tension type 0.15 2.2 Angio-CT 3
F 42 Tension type 0.17 0.2 Angio-MR 21
M 41 Tension type 0.43 1.0 Angio-CT 21
M 59 Tension type 0.69 1.0 Angio-CT 28 Prostate cancer
F 48 Migraine 0.29 0.2 Angio-MR 21
F 39 Migraine 0.40 2.8 Angio-CT 1
F 39 Tension type 0.23 1.0 Angio-CT 60
F 35 Migraine 0.16 0.2 Angio-CT 1
F 63 Tension type 0.22 1.2 Angio-CT 90
F 46 Migraine 1.05 13.8 Angio-CT 2 Urinary tract infection
F 25 Tension type 0.31 1.6 Angio-MR 4
M 24 Tension type 0.47 62.9 Angio-CT 90
F 54 Migraine 0.52 1.3 Angio-CT 2
F 30 Tension type 1.73 1.4 Angio-MR 5 Pregnancy
F 31 Tension type 0.21 0.4 Angio-CT 7
CRP — C-reactive protein; CT — computed tomography; F — female; M — male; MR — magnetic resonance
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.2
Box&Whisker Plot: DD (µg/ml)
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Figure 3. D-dimer concentrations in study groups
might correlate with greater thrombus extension and acute 
onset of symptoms.  
In the study by  Hiltunen et al., 71 patients included had 
a median level of DD of 1.40 mg/L (range 0.05–13.0mg/L). In 
nine (12%) patients DD was low, and of these seven presented 
with subacute and two with chronic mode of symptom dura-
tion. Elevated DD levels were associated with thrombosis in 
multiple sinuses (p = 0.044). Longer symptom duration has 
been correlated with low D-dimer levels (p = 0.010) [10]. Un-
fortunately, we did not confirm this in our preliminary study.
Venography may be beneficial in diagnosing CVST in 
ambiguous patients with higher levels of DD. Clinically useful 
biomarkers (such as DD) may predict CVST in the emergency 
department in ambiguous patients with or without unequivo-
cal MRI/MRV imaging. A higher DD level might help to decide 
whether venography is indicated in patients with headache as 
the only symptom.  
CVST symptoms can overlap in many ways with other 
neurological disorders. However, in the study by Meng et al. 
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[17], more than 20% of CVST occurred without a definitive 
medical history, and more than 70% of CVST occurred without 
focal neurological deficits. In the acute phase of CVST, DD 
(and additionally fibrinogen) were found to be abnormally 
elevated in 94.1% and 73.5% of cases, respectively. In the 
CVST group, the predominant features in MRI/MRV and 
DSA imaging included focal brain lesions, flow void signal 
loss, non-visualisation, and a local filling defect sign at the 
involved sinus [17].  
We agree with Gunes et al. [18], who concluded that the 
differential diagnosis of CVST should be always borne in mind 
in patients with a sudden, new or worsening headache, espe-
cially (but not only) in those at high risk of thrombosis [19]. 
It is important to note that in clinical practice low levels 
of DD cannot rule out CVST in patients with subacute or 
chronic disease. In many cases, high DD levels correlate with 
the acute onset of symptoms [10]. Thus, a higher DD level 
may be a predictive factor for CVST. But on the other hand, 
a normal concentration of D-dimer does not release us from 
performing more diagnostic tests to exclude CVST, as this 
cause of headache is potentially dangerous for the patient.  
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